Centralized pan-middle east survey on the undertreatment of hypercholesterolemia: Results from the cepheus study in arabian gulf countries

Angiology

Volumn 65, Issue 10, 2014, Pages 919-926

  Arafah, Mohamed ^a   Al Hinai, Ali T ^b   Mahmeed, Wael Al ^c   Al Rasadi, Khalid ^d   Tamimi, Omer Al ^e   Herz, Shorook Al ^f   Anazi, Faisal Al ^g   Nemer, Khalid Al ^h   Metwally, Othman ⁱ   Alkhadra, Akram ^j   Fakhry, Mohammed ^j   Elghetany, Hossam ^k   Medani, Abdel Razak ^l   Yusufali, Afzal Hussein ^l   Jassim, Obaid Al ^l   Hallaq, Omar Al ^m   Baslaib, Fahad Omar Ahmed S ⁿ   Alawadhi, Mahmoud ^o   Amin, Haitham ^p   Al Hashmi, Khamis ^b   Shehab, Abdullah ^q   more..

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^d SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^e HAMAD MEDICAL CORPORATION   (Qatar)

^f KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

^g MINISTRY OF HEALTH   (Saudi Arabia)

^h SECURITY FORCES HOSPITAL   (Saudi Arabia)

ⁱ KING FAHAD GENERAL HOSPITAL   (Saudi Arabia)

^j IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^k Soliman Fakieh Hospital   (Saudi Arabia)

^l DUBAI HOSPITAL   (United Arab Emirates)

^m American Hospital Dubai   (United Arab Emirates)

ⁿ RASHID HOSPITAL   (United Arab Emirates)

^o AL AMIRI HOSPITAL   (Kuwait)

^p BAHRAIN DEFENCE FORCE HOSPITAL   (Bahrain)

^q UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

more..

Author keywords

Arabian Gulf countries; cardiovascular; coronary; guidelines; hypercholesterolemia; lipids; low density lipoprotein

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; LIPID;

ADULT; ASIA; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIET RESTRICTION; FAMILY HISTORY; FEMALE; GOAL ATTAINMENT; HEALTH CARE SURVEY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION PROCESSING; KUWAIT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; OMAN; PRACTICE GUIDELINE; QATAR; REVIEW; SAUDI ARABIA; SEX DIFFERENCE; UNITED ARAB EMIRATES; AGED; ARAB; BLOOD; CORONARY DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH SURVEY; MEDICATION COMPLIANCE; MIDDLE AGED; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; ARABS; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUIDELINE ADHERENCE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MIDDLE EAST; QUALITY ASSURANCE, HEALTH CARE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84908871845     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713512414     Document Type: Review

References (34)

1. Husseini A, Abu-Rmeileh NM, Mikki N, et al. Cardiovascular diseases, diabetes mellitus, and cancer in the occupied Palestinian territory. Lancet. 2009 ; 373 (9677). 1764
2. Gehani Abdurrazzak A, Al-Hinai Ali T, Zubaid M, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study [published online November 2, 2012]. Eur J Preventive Cardiol. 2012 ;:
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 ; 326 (7404). 1423
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003 ; 24 (17). 1601-1610
5. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and, management of high blood cholesterol in adults (Adult Management Panel III): final report. Circulation. 2002 ; 106 (25). 3143-3421
6. Grundy SM, Cleeman JI, Merz CN, et al. National heart, lung, and blood institute; American college of cardiology foundation; American heart association. implications of recent clinical trials for the national cholesterol education program adult management panel III guidelines. Circulation. 2004 ; 110 (2). 227-239
7. A European society of cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997 ; 18 (10). 1569-1582
8. Eur Heart J. 2001 ; 22 (7). 554-572
9. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, management, and control of hypercholesterolemia among US adults. findings from the national health and nutrition examination survey, 1999 to 2000. Circulation. 2003 ; 107 (17). 2185-2189
10. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid management assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000 ; 160 (4). 459-467
11. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002 ; 113 (8). 625-629
12. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summa- ry. fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2007 ; 28 (19). 2375-2414
13. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and the international association for the study of obesity. Circulation. 2009 ; 120 (16). 1640-1645
14. Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in get with the guidelines (GWTG). Am Heart J. 2010 ; 160 (6). 1130-1136
15. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007 ; 28 (2). 154-159
16. Graham I, Atar D, Borch-Johnsen K, Boysen G, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (suppl 2). E1 - E40
17. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007 ; 167 (8). 847-852
18. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997 ; 18 (11). 1718-1724
19. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with non-adherence to statin therapy. Pharmacotherapy. 2005 ; 25 (8). 1035-1043
20. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 ; 297 (2). 177-186
21. West of scotland coronary prevention study: implications for clinical practice. Eur Heart J. 1996 ; 17 (2). 163-164
22. Shepherd J, Cobbe SM, Ford I, et al. For the west of scotland coronary prevention study group. prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995 ; 333 (20). 1301-1307
23. Sacks FM, Pfeffer MA, Moye LA, et al. For the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996 ; 335 (14). 1001-1009
24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4 S). Lancet. 1994 ; 344 (8934). 1383-1389
25. Downs JR, Clearfield Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998 ; 279 (20). 1615-1622
26. Simes RJ, Baker S, MacMahon S, et al Program and abstracts of the 47th Annual Scientific Session of the American College of Cardiology. Atlanta, GA: Abstract ; 1998.
27. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207
28. Hermans MP, Castro Cabezas M, Ferrie res J, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010 ; 26 (2). 445-454
29. Hatzitolios AI, Athyros VG, Karagiannis A, et al. IMPROVE collaborative group. implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol. 2009 ; 134 (3). 322-329
30. Daskalopoulou SS, Doonan RJ, Mikhailidis DP. Undertreatment of hypercholesterolemia. Curr Med Res Opin. 2010 ; 26 (2). 439-443
31. Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol. 2012 ; 19 (4). 781-794
32. Elisaf MS, Nikas N. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs - the CEPHEUS-Greece survey. Angiology. 2010 ; 61 (5). 465-474
33. Raal F, Schamroth C, Blom D, et al. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Africa. 2011 ; 22 (5). 234-240
34. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2 investigators. lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009 ; 120 (1). 28-34